2018) Type II kinase inhibitors targeting Cys-gatekeeper kinases display orthogonality with wild type and Ala/Gly-gatekeeper kinases.
ubiquitous mode of intracellular signaling, with about 30% of all proteins being phosphorylated 2, 3 . It is, therefore, to no surprise that aberrant expression and activation of this class of proteins often leads to a variety of diseases with about 244 kinases mapping to disease loci and cancer amplicons 1, 4, 5 .
One way to study kinase function and manage dysregulated kinases is through development of selective kinase inhibitors; however, due to the high degree of structural similarity, particularly in and around the ATP-binding pocket, it is often difficult to target an individual kinase with small-molecule inhibitors. One way to circumvent this issue is by employing a chemical-genetic strategy that takes advantage of a structurally conserved, mostly hydrophobic residue within the kinase active-site, termed the gatekeeper residue [6] [7] [8] . Mutation of this residue from a normally bulky residue to a smaller one, such as alanine (Ala) or glycine (Gly), engenders an analog-sensitive (AS) kinase containing a unique binding-site that can be exploited pharmacologically with bulky ATP-analogs such as 1NM-PP1 8 , 3MB-PP1 8 and the recently developed staralogs 7 (Figure 1A -D). This 'bump-hole' method has been utilized for the study of at least 85 different kinases, yet despite this level of success there are still a number of kinases, coined 'intolerant' kinases, that do not tolerate gatekeeper mutations [8] [9] [10] [11] .
To expand the scope of AS-technology, researchers have identified second-site mutations, or suppressor of Gly gatekeeper mutations (sogg), that restore the kinase activity to some 'intolerant' AS-kinases (applied to at least 11 kinases so far) when the gatekeeper is Gly or Ala 8, 10 . In addition, electrophile-sensitive (ES)-kinases can be selectively inhibited by electrophilic, bulky PP1-or ATP-analogs ( Figure 1E ) (e.g. fluoromethylketobenzyl (FMKB)-PP1, acrylamido-anilinoquinazolines (AQZ) and 5'-vinylsulfonyl adenosine (VSA)) by targeting cysteine (Cys)-mutations within the gatekeeper or other positions vicinal to the ATP-binding pocket (i.e. in the Gly-rich loop (G-loop) or hinge region, Figure 1A) 9, [12] [13] [14] [15] [16] [17] [18] . However, these approaches appear to be highly specific to individual kinases and not widely applicable. This also limits the possibility to differentially inhibit two kinases with two orthogonal chemical genetic systems. Such a dual bio-orthogonal approach would be ideal for investigating kinase signaling crosstalk, synthetic lethality and many other areas of systems biology and translational research across a diverse set of kinase drug targets.
In this study, we report the development of a new chemical-genetic approach based on a Cysgatekeeper mutation and non-covalent, type II mode of kinase inhibition that targets the inactive "DFG-out" kinase conformation ( Figure 1C) 19 . We verified this approach with three divergent Ser/Thr-kinases: Greatwall kinase (GWL), Aurora-A kinase (AAK) and Cyclindependent kinase-1 (Cdk1). To demonstrate compound efficacy in cells, we measured phosphorylation of the physiologic GWL substrate -endosulfine (ENSA) 20 and cellular proliferation, a phenotype functionally linked to GWL activity 21, 22 , in wild type (WT)-and M110C (MC)-GWL expressing mouse embryonic fibroblasts (MEFs). ASDO2 (Analog-Sensitive "DFG-Out" kinase inhibitor-2) specifically inhibited production of phospho-ENSA (pENSA) and attenuated proliferation in MC-GWL expressing MEFs, but not in WT-GWL expressing cells. Together, these data support expanding the AS-kinase inhibitor tool set with "DFG-out" targeting ASDO inhibitors, which in combination allow for the independent targeting of at least two distinct kinases ( Figure 1C ).
RESULTS AND DISCUSSION
Approaches utilized to expand analog-sensitive kinase technology. The starting point of this study was an effort to develop an AS-version of microtubule-associated Ser/Thr kinase-like (MASTL) protein, commonly known as GWL, in order to investigate its mitotic functions and role in the cell cycle 23 . Over-expression and immunoprecipitation of FLAGtagged GWL constructs provided a means to assess the activity of a cohort of GWL mutants ( Figure 2A ). This assay demonstrated that GWL is an 'intolerant' kinase evidenced by the inactivity of the AS1 (M110G) and AS2 (M110A) GWL kinase alleles (Figures 2B-C & S1A), and neither sogg mutations nor the ES-kinase approach were capable of generating an AS-GWL system (Figure S1A-G). In the first instance, we decided to make sogg mutations at the analogous positions in GWL, which included mutations that were previously successful for kinases such as Pto (L68I), APH(3')-IIIa (N268T) and GRK2 (S268V) ( Figure S1G ) 10 . Only one of these mutations, V61I-GWL, augmented GWL activity, evidenced by increased myelin basic protein phosphorylation, but did not restore activity of the double mutant V61I/M110A-GWL ( Figure S1B ). Bioinformatically, we identified sites in the G-loop consensus sequence (GxGxxG) that deviated from other AGC kinases, but reversion mutations in the G-loop, made to adopt the more common amino acids, had a meagre (S42G) to no (S42G/A45S) effect in combination with M110A-GWL ( Figure S1 , panels A & C) 24 .
Initial efforts to identify sogg mutations for Ala-gatekeeper GWL were unsuccessful, and thus we hypothesized that other small amino acids, presumably preserving an expanded hydrophobic ATP-binding pocket, might be useful in combination with previously identified or new sogg mutations. To explore this idea further, the gatekeeper position was scanned with relatively small amino acids, which led to the discovery that MC-GWL-mediated phosphorylation of ENSA was only 4-fold less compared to WT ( Figure 2B -C). Furthermore, through FACS analysis, we showed that RNAi-resistant MC-GWL, unlike M110A-GWL, was able to restore G1, S and G2/M cellular levels to the same extent as an siRNA-resistant WT rescuing plasmid in GWL depleted HeLa cells (Figures 2D-I & S2A-F). This result inspired the generation of an ES-kinase system; however, the electrophilic inhibitors AG1-2 and FMKB-PP1 (Figures 1E, S1D-E & S2), which were validated against T338C-c-Src, did not robustly inhibit MC-GWL at 20 M concentrations (Figure S1D-E) 9 . Of the other small gatekeeper mutations, M110T-GWL displayed ~8% activity compared to WT, and thus we made Cys mutations in an M110T-GWL mutant to mimic the cysteines in the hinge regions of EphB3 (C717) and EGFR (C797); M110T/G116C and M110T/D117C 13, 15 . In combination with a Thr gatekeeper, similar mutations in EphB1 (G703C) and c-Src (S345C), to name a few, are targetable using electrophilic quinazoline-based inhibitors (e.g. AQZ, Figure 1D ), but due to the inactivity of these GWL double mutants, we were not able to apply them (Figure S1F-G) 13, 15 .
AD57-analogs specifically target MC-GWL in vitro.
Due to the inefficacy of known ESkinase inhibitors against MC-GWL, we decided to generate novel inhibitors based on the structure of AD57 25 (Figures 3A & S3 ). We surmised that replacement of the urea linker with an acrylamide linker might allow selective targeting by a nucleophilic Cys-mutant 16 . AD57 also seemed like an ideal candidate as it selectively inhibited MC-GWL with an IC50 value of 10.6 ± 0.4 M and displayed no inhibitory activity against WT-GWL ( Figure 3 Figure 4A ) 9, 26 . The resulting compound contained an acrylamide linker bridging the pyrazolopyrimidine moiety with a trifluoromethylbenzoyl group. This feature is similar to a trifluoromethylphenyl group, which is commonly incorporated into some type II kinase inhibitors 19, 27 . ASDO1 (Analog-Sensitive "DFG-Out" kinase inhibitor-1) ( Figure 3A ) completely abrogated MC-GWL activity at a concentration of 20 M without inhibiting WT-GWL ( Figure   S3 ). By assaying AD57 and ASDO1 more rigorously using the immunoprecipitation-based kinase assay with ENSA as substrate, we were able to show that ASDO1 exhibited a >60-fold improvement in potency against MC-GWL with an IC50 value of 0.17 ± 0.09 M and remained exquisitely selective for MC-vs. WT-GWL even up to concentrations as high as 100 M
Structural studies using an AD57-c-Src co-crystal structure predicted that formal halogenation of the terminal phenyl ring with ortho-fluorine and para-chlorine substituents would fine-tune the selectivity profile of AD57. Indeed, these halogenated AD57-derivatives maintained inhibitory activity toward Ret, Raf, Src and S6K, reduced mTor inhibition and led to significantly less toxicity in a multiple endocrine neoplasia type 2 Drosophila model system 25 . In an attempt to fine-tune the selectivity of ASDO1 toward MC-vs. WT-GWL, we synthesized halogenated and bulkier, non-halogenated ASDO-derivatives by first incorporating acetophenones into the microwave-assisted aldol-condensation with glyoxylic acid to yield 3-benzoylacrylic acids 26 , which after conversion to acid chlorides were later coupled with anilinopyrazolopyrimidines hydrophobic pocket unique to the inactive kinase conformation 19, 28 . In contrast to DO1, the lack of inhibitory activity of DO2 hints at the possibility that this series of compounds, like the parent compound AD57, might stabilize the inactive 'DFG-out' kinase conformation.
To establish the importance of the bulkier central ring of ASDO6, both ASDO2 & 6 were subjected to a rigorous kinase inhibition-profiling screen (International Centre for Kinase Profiling, University of Dundee Kinase Profiling Express Screen). At 1 M, ASDO2 inhibited 15 of 50 kinases with inhibitory activity ≥ 60% (60-95%); however, as is the case with classical AS-kinase inhibitors, the increased bulk of the central benzene ring of ASDO6 likely accounts for the decrease in number of WT-kinases targeted with inhibitory activity > 60% (62-84%); only 4 of 50 kinases. Note that the higher end of the inhibitory range decreased from 95% for ASDO2 to 84% for ASDO6, providing further evidence that the bulkier ASDO6-derivative is more refractory toward WT-kinases ( Figures 4E & S5A-B ). 
ASDO2 selectively inhibits MC-GWL in cells. Although ASDO6 inhibited less WT-kinases
with inhibitory activity >60% ( Figure 4E ), ASDO2 displayed greater potency and specificity in GWL and AAK kinase assays ( Figure 4A ). We, therefore, opted to assess the effects of Figure 6E ).
ASDO2 displays relatively slow-on/slow-off binding/dissociation kinetics. At this point,
it was still unclear how ASDO2/6 mono-specifically targeted MC-vs. WT-GWL (i.e. as a type I or II inhibitor) and the presence of an electrophilic, doubly-activated olefin brings to question whether or not it interacts with MC-GWL in a reversible or irreversible manner. To further probe the mechanism of action of ASDO2, we investigated the reversibility of inhibition in comparison to a type I inhibitor (staurosporine) and the parent type II inhibitor AD57; note that type I inhibitors generally display fast-on/fast-off binding/dissociation kinetics, whereas type II inhibitors generally display slow-on/slow-off binding/dissociation kinetics 28, 30 .
Initially, a washout experiment with MC-GWL supported the notion of an ES-kinase model system. Evidence for this is seen by the failure of ASDO2-treated ( Figure 7F ). Taken together, these data suggest that ASDO2 shares similar slow-on/slow-off binding/dissociation kinetics as the type II inhibitor AD57, but could also be acting, to a small extent, in an irreversible manner as inhibition marginally improves over time ( Figure 7F ).
Unfortunately, expression, purification and X-ray crystallography of full-length GWL has proven to be a major technical challenge; therefore, to pin down the exact binding mode of ASDOs in GWL, technical innovations in GWL structural biology are required 21 .
ASDO2/6 demonstrates a type II inhibitor binding mode with LC-AAK. To cement the binding-mode of ASDO2/6, we solved X-ray co-crystal structures with LC-AAK: ASDO2 (PDB: 6HJK) and ASDO6 (PDB: 6HJJ) 31 . Both compounds were sandwiched between the N-and Cterminal lobes bound to the ATP-binding pocket, making the expected interactions with the backbone of the hinge region (Glu211 and Ala213) and stretching all the way to the C-helix, displacing it in comparison to the WT-AAK ADP-bound structure (PDB: 4CEG, Figure S7A Figures 8A-B & S7D) 19 . In fact, overlay of the Asp274 residues of the 1NM-PP1-(type I, PDB: 4LGH) and ASDO2/6-(type II) bound structures illustrates another key difference between type I and II inhibitors: The Asp residue flips 180 o going from an active to an inactive conformation, allowing Phe to pack against ASDO6 ( Figures 8A-B & S7D) 19 .
In the ASDO6-bound structure, Cys210 appears to form a weak, electrostatic interaction with the amide 'N', and the Ala273 backbone carbonyl forms a strong hydrogen bond with the same amide group, serving as a molecular clamp that also brings to light the importance of the cysteine residue ( Figure 8C ). Comparing the ASDO2-and 6-bound structures also sheds light on the molecular level basis for the decrease in WT-kinase targeting by ASDO6; that ASDO6 prefers binding to AAK only when the gatekeeper residue is a polar amino acid such as cysteine. Alignment of these structures shows that the methylphenyl ring of ASDO6 twists in the direction of Cys210, bringing the amide closer to the Ala273 backbone; however, a water molecule fills the gap between ASDO2, Cys210 and the Ala273 backbone with all three elements forming a hydrogen-bonding network in the ASDO2-bound structure
As a result of placing the polar amide group of ASDO6 in closer proximity to the gatekeeper residue, WT AAK, which harbors a hydrophobic Leu210 gatekeeper residue, would disfavor and destabilize the ASDO6-bound conformation ( Figure 8F ). Based on this hypothesis, other hydrophobic amino acids such as Ala should also attenuate ASDO6 inhibitory activity and replacing cysteine with a less polar amino acid or with Gly, which lacks a side-chain, should abolish the molecular clamp mechanism and abrogate the ASDO6-GWL interaction as well.
To test these hypotheses, we over-expressed, immunoprecipitated and treated FLAG-M110A-GWL with ASDO6 up to a concentration of 10 M. As predicted, ASDO6 was not able to inhibit M110A-GWL, nor was 3MB-PP1 able to inhibit M110C-GWL in vitro ( Figure 8G-H ), suggesting the two systems work independently of each other and could be used to differentially inhibit other combinations of kinases based on gatekeeper mutations to either cysteine or Ala/Gly.
Discussion and Conclusions
AS-kinase technology has been employed to dissect the cellular functions of individual kinases across the kinase family, but there are still a number of kinases that remain averse to this methodology. In order to apply AS-kinase technology, mutations that engender sensitivity to pharmacologic inhibition must also maintain sufficient kinase activity so that the mutant kinase can recapitulate WT cellular function. There are many ways to broaden the scope of AS-kinase technology such as making sogg mutations that rescues the activity of 'intolerant' kinases when an Ala/Gly-gatekeeper mutation is present 10 . Also, over the years, a number of different AS-and ES-systems have been developed that incorporate amino acids other than Ala or Gly, e.g. Cys or Thr 9, 13, 17, 18 , into the gatekeeper position, but so far, these systems have not been widely utilized in the field; though some are still in their infancy. In terms of AS-systems that have proven fruitful, a number of new reagents such as staralogs 7 offer even greater specificity and potency, but to expand the scope of AS-kinase technology further we need not focus solely on engineering inhibitors against the active kinase conformation, but take full advantage of all modes of pharmacologic inhibition. To date, type II inhibitors have been left out of the loop when it comes to the development of chemogenomic technology, but this study is the first to provide an example of a chemical genetic system based on Cys-mutant kinase inhibition with a type II inhibitor; a system that we now refer to as the ASDO (Analog-Sensitive 'DFG-Out')-kinase system ( Figure 1B & C) . Furthermore, type I and II kinase inhibitors bind to disparate kinase conformations resulting in their catalytic inactivation 19, 27, 28 . Due to evolutionary pressure to preserve the catalytically active kinase conformation, type I inhibitors encounter a very similar ATP-binding pocket across the kinome, made exploitable through the 'bump-hole' method. The inactive kinase conformation is not bound by this evolutionary pressure and is more varied 28 , which may have hampered previous attempts to generate a type II inhibitor-based ASDO-kinase system.
Despite this variability, we systematically optimized the ASDO-scaffold to engender a smallmolecule inhibitor that displays generality across at least three divergent Ser/Thr-kinases bearing a Cys-gatekeeper, so far, and ASDO2/6 display bio-orthogonality versus WT kinases ( Figures 1B & 4F ). As this system not only appears to take advantage of steric complementarity, but also electrostatic interactions, to engender specificity toward Cysgatekeeper kinases, we hypothesized that it may act independently of the canonical AS-kinase system, which is based solely on steric complementarity. This theory was validated in vitro and will likely change the landscape of future studies involving signaling pathways in cells and disease models. These multiple AS/ASDO-kinase systems along with the Ele-Cys and ESkinase systems (systems that utilize electrophilic-quinazoline and 5'-electrophilic adenosine scaffolds) now provide an ensemble of chemical genetic tools to explore differential and independent kinase inhibition across at least two kinases in cells. Lastly, this system exploits binding to and stabilizing the 'DFG-out' conformation of kinases and we demonstrated the tenability of isolating these ASDO-co-crystal structures using X-ray crystallography. To date, X-ray crystal structures of inactive kinase conformations across the kinome are sparse 19, 28 , but the ASDO system could potentially be used to generate X-ray crystal structures of other inactive kinase conformations. This technology, therefore, has great potential to galvanize drug discovery efforts by providing new 'DFG-out' X-ray crystal structures that would assist with rational, in silico drug design efforts.
METHODS

Kinase Assays
Immunoprecipitation and radioactive kinase assays were carried out as published previously 21 . The catalytically dead mutant D174A-GWL was used as a control for inhibition.
Aurora-A and xlCDK1 assays were carried out similarly to FLAG-GWL immunoprecipitation kinase assays. N-terminally tagged FLAG-Aurora-A 32 kinase and C-terminally tagged MYC-xlCDK1 were over-expressed in HEK 293T cells using the standard phosphate-mediated transfection method. Cdk1 assays were carried out by incubating HEK 293T lysates containing MYC-CDK1 with 4 g of anti-c-Myc antibody and immunoprecipitation with 5 l of Dynabeads™ Protein G (Thermofisher). To detect phosphorylated histones H1 (CDK1, Fig.   S5A ) and H3 (1g/20l reaction (AAK)) the standard kinase reaction was spiked with 0.075
MBq -32 P ATP (PerkinElmer) per 20 l reaction. After the reaction was stopped with 5 l 5X SDS loading buffer and boiled for 5 min at 95 °C, the mixture was resolved via SDS-PAGE (4-15% Criterion pre-cast gels (Bio-Rad Laboratories) or 13% v/v SDS-polyacrylamide gels).
Staining with coomassie-blue revealed ~28 and 21 kDa bands respectively that were imaged by autoradiography. All concentration-dependent kinase assays were performed thrice and quantitation of activity (Phospho-signal(radioactive/densitometry):kinase loading ratio) using ImageJ (1.47v) of the average normalized % kinase activity ± S.D. was plotted using Prism 6.0. Non-linear regression using Prism 6.0 was used to calculate IC50 values.
Crystallization and Data Collection
Aurora-A (containing mutations L210C, C290A and C393A) 31 was co-crystallized with ASDO2 and ASDO6 by mixing purified protein (500 µM) with compound (ASDO2, 500 µM; ASDO6, 
Phasing, Model Building and Refinement
All diffraction data were collected at 100K. Autoprocessed datasets were generated by automatic integration of the data using the software package XDS followed by processing using the Pointless and Scala programs from the CCP4 software suite. Phases were obtained by molecular replacement using Phaser with a high resolution structure of ADP- 
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